<DOC>
	<DOCNO>NCT02751827</DOCNO>
	<brief_summary>In order ass important issue safety antiangiogenic TKI geriatric population set project aim identify , among clinical , biological , pharmacokinetic data , predictive factor severe toxicity antiangiogenic TKI ( sunitinib , sorafenib , pazopanib , regorafenib , axitinib ) patient 75 year-old .</brief_summary>
	<brief_title>Predicting Severe Toxicity Targeted Therapies Elderly Patients With Cancer</brief_title>
	<detailed_description>This prospective cohort collection biological sample , include 300 patient &gt; 75 year-old treat multicenter antiangiogenic TKI regularly approve metastatic cancer . Data clinical biological characteristic patient , disease treatment well pharmacogenomics centrally collect begin treatment . Drug exposure-safety analysis perform assessment drug level ( Cmin ) . Primary endpoint severe toxicity define treatment-related death , hospitalization disruption treatment three week .</detailed_description>
	<criteria>Age â‰¥ 75 year Treatment pazopanib , regorafenib , sorafenib , sunitinib , axitinib context market authorization Voluntary sign date write informed consent prior study specific procedure . Patient treat context clinical trial Patient alter mental status psychiatric disorder , opinion investigator , would preclude valid patient consent</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>